Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Presentation on the biosimilar Enoxaparin of ROVI
Mon, 13/03/2017 - 10:46
0 min
ENOXAPARIN BIOSIMILAR.png
Download related document
Select rating
Give Presentation on the biosimilar Enoxaparin of ROVI 1/5
Give Presentation on the biosimilar Enoxaparin of ROVI 2/5
Give Presentation on the biosimilar Enoxaparin of ROVI 3/5
Give Presentation on the biosimilar Enoxaparin of ROVI 4/5
Give Presentation on the biosimilar Enoxaparin of ROVI 5/5
No votes yet
Related
The López-Belmonte family increase their interest in ROVI to 63.1%
The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in...
1 min
27/05/2019
First quarter 2019 results presentation
0 min
08/05/2019
ROVI reports operating revenue growth of 8%, underpinned by outstanding low-...
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 8% to 82.2 million euros in the first quarter of 2019, mainly driven...
5 min
08/05/2019
See More
Email
Facebook
Twitter
LinkedIn
ENOXAPARIN BIOSIMILAR.png